Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose aspirin modulation of platelet activation in inflammatory bowel disease
2013-002143-29Phase 3Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of aspirin in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease, sponsored by Policlinico Gemelli. Primary endpoints: Serum thromboxane B2 and Urinary 11-dehydro-thromboxane B2. Started Jun 2013; status: terminated.
02
Drugs
aspirin
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2013-002143-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002143-29.